6.45
-0.2(-3.01%)
Currency In USD
| Previous Close | 6.65 |
| Open | 6.65 |
| Day High | 6.77 |
| Day Low | 6.33 |
| 52-Week High | 61.9 |
| 52-Week Low | 4.64 |
| Volume | 123,943 |
| Average Volume | 222,154 |
| Market Cap | 78.93M |
| PE | -1.75 |
| EPS | -3.68 |
| Moving Average 50 Days | 6.44 |
| Moving Average 200 Days | 21.46 |
| Change | -0.2 |
If you invested $1000 in Corbus Pharmaceuticals Holdings, Inc. (CRBP) 10 years ago, it would be worth $55.99 as of May 09, 2025 at a share price of $6.45. Whereas If you bought $1000 worth of Corbus Pharmaceuticals Holdings, Inc. (CRBP) shares 5 years ago, it would be worth $32.38 as of May 09, 2025 at a share price of $6.45.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Corbus Pharmaceuticals to Present at the 2025 RBC Capital Markets Global Healthcare Conference
GlobeNewswire Inc.
Yesterday at 12:00 PM GMT
Norwood, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in a fireside chat and o
Corbus Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Study of Next-Generation CB1 Inverse Agonist CRB-913 for the Treatment of Obesity
GlobeNewswire Inc.
Mar 28, 2025 12:00 PM GMT
CB1 inverse agonism is a clinically validated mechanism to induce weight loss CRB-913 is markedly more peripherally restricted compared to monlunabant and rimonabantSAD/MAD Phase 1 trial scheduled for completion Q3 2025 and Phase 1b dose-range findin
Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences
GlobeNewswire Inc.
Feb 25, 2025 1:00 PM GMT
NORWOOD, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in the following upcomi